•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Verastem Weighs Partnership or Solo Launch as Cancer Drug Trials Advance
Verastem Bets on Higher Cancer Drug Dose as It Maps Potential Approval Path
Verastem Targets Accelerated Approval for Pancreatic Cancer Drug, Expands Trial Plans
What Verastem (VSTM) Said on Its Q3 Earnings Call
Verastem, Inc. (VSTM) Q3 2026 Earnings Call Transcript
Verastem (VSTM) Reports Q3 Loss, Misses Revenue Estimates
Verastem Oncology Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates
Verastem Oncology to Participate in Upcoming November Investor Conferences
Verastem Oncology to Report Third Quarter 2026 Financial Results on November 5, 2026
Verastem, Inc. (VSTM) Discusses New Clinical Data for VS-7375 KRAS G12D Inhibitor in Pancreatic, Lung, and Colorectal Cancers Transcript
Verastem's KRAS G12D Drug Posts Pancreatic Responses, Advances to Phase III
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers
Verastem Is Getting a New CEO, $250 Million, and a Shot at Another Cancer Drug
Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants
Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan
VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Disease (One Confirmed)
Does Verastem (VSTM) Have the Potential to Rally 79% as Wall Street Analysts Expect?
Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Verastem (NASDAQ:VSTM) Given Buy Rating at BTIG Research